BioAtla is a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancers. Our conditionally active biologics, or CABs, enable us to target known and widely validated tumor antigens that have previously been difficult or impossible to target. Our approach is to identify the necessary targeting and potency required for cancer cell destruction, while aiming to eliminate or greatly reduce on-target, off-tumor toxicity—one of the fundamental challenges of existing cancer therapies. We have initiated Phase 2 trials for our two latest stage ADC product candidates in multiple high unmet need cancer indications, including sarcoma, I/O failure NSCLC and melanoma. We are also supporting investigator-initiated trials in platinum-resistant ovarian cancer. Our goal is to develop well-tolerated, novel cancer therapies that provide cures or extended survival to ensure patients’ improved quality of life.